<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We studied the potential value of oral <z:chebi fb="0" ids="7731">ofloxacin</z:chebi> (200 mg twice daily) for selective decontamination and <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> prevention in 40 granulocytopenic patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> of <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>, hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> or severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The quality of selective decontamination was acceptable with rapid elimination of Enterobacteriaceae from the alimentary tract, only a slight decrease in concentrations of anaerobes in faeces, and a small number of newly acquired transient (twelve isolates in seven patients) or colonizing (six strains with 28 isolates in four patients) aerobic <z:mp ids='MP_0001795'>gram-negative</z:mp> rods and Staphylococcus aureus (one isolate) recovered from 672 surveillance cultures from faeces, oral washings and urine </plain></SENT>
<SENT sid="2" pm="."><plain>Two of three patients colonized with <z:chebi fb="0" ids="7731">ofloxacin</z:chebi>-resistant Pseudomonas aeruginosa strains developed <z:e sem="disease" ids="C0033817" disease_type="Disease or Syndrome" abbrv="">Pseudomonas infections</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>A total of twelve acquired <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> was observed </plain></SENT>
<SENT sid="4" pm="."><plain>Six were microbiologically documented <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, <z:hpo ids='HP_0000001'>all</z:hpo> caused by <z:chebi fb="0" ids="7731">ofloxacin</z:chebi>-resistant bacteria (two P. aeruginosa, two Staphylococcus epidermidis, one Aerococcus viridans, one Micrococcus sp.) </plain></SENT>
<SENT sid="5" pm="."><plain>Tolerance was acceptable with no serious side effects observed </plain></SENT>
<SENT sid="6" pm="."><plain>Mean drug concentrations in serum and saliva were comparable to those determined in healthy volunteers and were found to be higher in saliva than in serum </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that <z:chebi fb="0" ids="7731">ofloxacin</z:chebi> may be studied as an effective alternative to <z:chebi fb="0" ids="45924">trimethoprim</z:chebi>-<z:chebi fb="0" ids="9332">sulfamethoxazole</z:chebi> for selective decontamination and <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> prevention in severely granulocytopenic patients </plain></SENT>
<SENT sid="8" pm="."><plain>Careful monitoring of colonizing Pseudomonas spp. with decreased <z:chebi fb="0" ids="7731">ofloxacin</z:chebi> sensitivity, however, seems necessary </plain></SENT>
</text></document>